Revita in 2026: Can a One-Time Procedure Keep the Weight Off After You Stop GLP-1s?

On October 16, 2026, Fractyl Health announced that its REMAIN-1 pivotal study met its six-month co-primary endpoint. The trial enrolled 308 adults with obesity (BMI 30–45) and no type 2 diabetes, all new to GLP-1 therapy. Everyone first took tirzepatide — the active ingredient in Zepbound and Mounjaro — until they had lost at least 15% of their body weight. Then they stopped the medication and were randomized 2 to 1 to either the Revita procedure or a sham endoscopy, with neither patients nor assessors knowing who got which.

Six months after stopping tirzepatide, patients who received Revita had regained an average of 5.1% of their body weight, versus 8.2% in the sham group — a statistically significant difference (p=0.0023), as reported by HCPLive. Put another way, Revita patients kept roughly 80% of the weight they had lost on tirzepatide, while sham patients kept about 67%.

Revita is not a surgery and not an implant. It's an outpatient endoscopic procedure: a thin catheter is passed through the mouth to the duodenum — the first segment of the small intestine — where it resurfaces the mucosal lining with controlled ablation. The duodenum plays an outsized role in sensing nutrients and signaling hormones that regulate blood sugar and appetite. Fractyl's hypothesis is that in chronic metabolic disease this lining becomes dysfunctional, and that remodeling it helps "reset" those signals.

The FDA has granted Revita Breakthrough Device designation for weight maintenance in people with obesity who stop GLP-1 therapy — a status that speeds up review but does not guarantee approval. An exploratory analysis in the trial also hinted that technique matters: patients whose procedure ablated 20 cm or more of the duodenum regained just 3.8% of body weight, about 53% less than the sham group.

The headline result — 5.1% versus 8.2% regain — is a real, measurable difference, but it's worth reading carefully. Patients who got the procedure still regained some weight on average; Revita slowed regain rather than stopping it for everyone. The more striking figure may be the responder analysis: 32% of Revita patients stayed weight-stable or kept losing after stopping tirzepatide, compared with 18% of sham patients — and that gap widened at each follow-up visit.

It's also notable how strong the sham group's "placebo" performance was: even without an active procedure, patients in a structured trial with regular follow-up kept about two-thirds of their weight loss at six months. That echoes what we covered in our piece on a 2026 trial of structured support programs — accountability and follow-up by themselves meaningfully blunt weight regain.

Through the September 24, 2026 data cutoff, Fractyl reported no device- or procedure-related serious adverse events, no deaths, and no unanticipated device effects. Side effects related to the procedure were mostly mild — things like temporary GI discomfort — and 94% occurred within the first week, consistent with what's expected after an upper GI endoscopy.

The caveats: these are company-reported topline results, not yet published in a peer-reviewed journal. The second co-primary endpoint — the share of patients still maintaining at least 5% weight loss a full year after stopping tirzepatide — won't read out until the first quarter of 2027. The responder and ablation-length analyses were post hoc, meaning they're promising signals rather than proven findings. And the trial enrolled people without diabetes who responded well to tirzepatide, so results may not generalize to everyone.

For now, Revita remains investigational in the United States. Fractyl plans to submit a De Novo marketing application to the FDA in late 2026, with potential authorization in late 2027 and a U.S. launch targeted for early 2028 at the soonest. A temporary CPT billing code takes effect January 1, 2027, but pricing hasn't been announced, and new-technology codes like this one are often not routinely covered by insurance at first.

That means in 2026, the proven paths to keeping weight off are still the ones available today: staying on your GLP-1 at a maintenance dose, tapering gradually under medical supervision rather than stopping abruptly, and building the nutrition, strength training, and follow-up habits that the sham arm of this very trial showed are worth real percentage points. If nausea or side effects are pushing you to quit your medication, dose adjustments and anti-nausea support are often a better first move than discontinuing.

If you're thinking about starting, continuing, or coming off a GLP-1, the deciding factor should be a plan — not a cliff. JoeyMed's licensed providers can evaluate whether treatment like tirzepatide is right for you, help you titrate to a dose you can stay on, and build a maintenance strategy for the long run. GLP-1 medications aren't right for everyone: your provider will screen for contraindications such as a personal or family history of medullary thyroid carcinoma or MEN 2, and common side effects like nausea, constipation, and fatigue are managed best with clinical follow-up. Visit JoeyMed Weight Loss to complete a free online consultation and see your options — and keep an eye on this space as the first-ever "weight maintenance procedure" moves toward an FDA decision.